PURPOSE: Desmoplastic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving the peritoneum, has a long-term survival of < 20% despite aggressive multimodality treatment. B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy. PATIENTS AND METHODS: In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal antibody 131I-omburtamab in patients with DSRCT or other B7H3-expressing tumors involving the peritoneum. After thyroid blockade, patients received 131I-omburtamab as a single IP injection at escalated activities from 1.11 to 3.33/GBq/m2. A prior tracer dose of IP 74 MBq124I-omburtamab was used for radioimmuno-positron emission tomography imaging. Each injection was followed by IP saline infusion. RESULTS: Fifty-two patients (48, three, and one with DSRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) received IP 131I-omburtamab administered on an outpatient basis. Maximum tolerated dose was not reached; there were no dose-limiting toxicities. Major related adverse events were transient: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1), and grade 1 (10%) and grade 2 (52%) pain lasting < 2 hours related to saline infusion. Hypothyroidism was not observed, and antidrug antibody was elicited in 5%. Mean (± SD) projected peritoneal residence time was 22.4 ± 7.9 hours. Mean projected absorbed doses for 131I-omburtamab based on 124I-omburtamab dosimetry to normal organs were low and well within tolerable limits. More than 80% 131I remained protein bound in blood 66 hours after RIT. On the basis of peritoneal dose and feasibility for outpatient administration, the recommended phase II activity was established at 2.96 GBq/m2. Patients with DSRCT receiving standard whole-abdominal radiotherapy after RIT did not experience unexpected toxicity. CONCLUSION: IP RIT 131I-omburtamab was well tolerated with minimal toxicities. Radiation exposure to normal organs was low, making combination therapy with other anticancer therapies feasible.
PURPOSE: Desmoplastic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving the peritoneum, has a long-term survival of < 20% despite aggressive multimodality treatment. B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy. PATIENTS AND METHODS: In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal antibody 131I-omburtamab in patients with DSRCT or other B7H3-expressing tumors involving the peritoneum. After thyroid blockade, patients received 131I-omburtamab as a single IP injection at escalated activities from 1.11 to 3.33/GBq/m2. A prior tracer dose of IP 74 MBq124I-omburtamab was used for radioimmuno-positron emission tomography imaging. Each injection was followed by IP saline infusion. RESULTS: Fifty-two patients (48, three, and one with DSRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) received IP 131I-omburtamab administered on an outpatient basis. Maximum tolerated dose was not reached; there were no dose-limiting toxicities. Major related adverse events were transient: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1), and grade 1 (10%) and grade 2 (52%) pain lasting < 2 hours related to saline infusion. Hypothyroidism was not observed, and antidrug antibody was elicited in 5%. Mean (± SD) projected peritoneal residence time was 22.4 ± 7.9 hours. Mean projected absorbed doses for 131I-omburtamab based on 124I-omburtamab dosimetry to normal organs were low and well within tolerable limits. More than 80% 131I remained protein bound in blood 66 hours after RIT. On the basis of peritoneal dose and feasibility for outpatient administration, the recommended phase II activity was established at 2.96 GBq/m2. Patients with DSRCT receiving standard whole-abdominal radiotherapy after RIT did not experience unexpected toxicity. CONCLUSION: IP RIT 131I-omburtamab was well tolerated with minimal toxicities. Radiation exposure to normal organs was low, making combination therapy with other anticancer therapies feasible.
Authors: Dave R Lal; Wendy T Su; Suzanne L Wolden; Kenneth C Loh; Shakeel Modak; Michael P La Quaglia Journal: J Pediatr Surg Date: 2005-01 Impact factor: 2.545
Authors: Kim Kramer; Brian H Kushner; Shakeel Modak; Neeta Pandit-Taskar; Peter Smith-Jones; Pat Zanzonico; John L Humm; Hong Xu; Suzanne L Wolden; Mark M Souweidane; Steven M Larson; Nai-Kong V Cheung Journal: J Neurooncol Date: 2009-11-05 Impact factor: 4.130
Authors: D Billmire; C Vinocur; F Rescorla; B Cushing; W London; M Schlatter; M Davis; R Giller; S Lauer; T Olson Journal: J Pediatr Surg Date: 2004-03 Impact factor: 2.545
Authors: Andrea A Hayes-Jordan; Brian A Coakley; Holly L Green; LianChun Xiao; Keith F Fournier; Cynthia E Herzog; Joseph A Ludwig; Mary F McAleer; Peter M Anderson; Winston W Huh Journal: Ann Surg Oncol Date: 2018-01-30 Impact factor: 5.344
Authors: Eleanor Marshall Osborne; Tina Marie Briere; Andrea Hayes-Jordan; Lawrence B Levy; Winston W Huh; Anita Mahajan; Peter Anderson; Mary Frances McAleer Journal: Radiother Oncol Date: 2015-10-30 Impact factor: 6.280
Authors: C Honoré; V Atallah; O Mir; D Orbach; G Ferron; C LePéchoux; J B Delhorme; P Philippe-Chomette; S Sarnacki; S Msika; P Terrier; O Glehen; H Martelli; V Minard-Colin; F Bertucci; J Y Blay; S Bonvalot; D Elias; A LeCesne; P Sargos Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Milan Grkovski; Shakeel Modak; Pat B Zanzonico; Jorge A Carrasquillo; Steven M Larson; John L Humm; Neeta Pandit-Taskar Journal: J Nucl Med Date: 2021-12-02 Impact factor: 11.082
Authors: Christopher S Chandler; Meghan M Bell; Sebastian K Chung; Darren R Veach; Edward K Fung; Blesida Punzalan; Daniela Burnes Vargas; Mitesh Patel; Hong Xu; Hong-Fen Guo; Brian H Santich; Pat B Zanzonico; Sébastien Monette; Garrett M Nash; Andrea Cercek; Achim Jungbluth; Neeta Pandit-Taskar; Nai Kong V Cheung; Steven M Larson; Sarah M Cheal Journal: Mol Cancer Ther Date: 2021-10-19 Impact factor: 6.009
Authors: Celso Abdon Mello; Fernando Augusto Batista Campos; Tiago Goss Santos; Maria Leticia Gobo Silva; Giovana Tardin Torrezan; Felipe D'Almeida Costa; Maria Nirvana Formiga; Ulisses Nicolau; Antonio Geraldo Nascimento; Cassia Silva; Maria Paula Curado; Suely Akiko Nakagawa; Ademar Lopes; Samuel Aguiar Journal: Cancers (Basel) Date: 2021-01-28 Impact factor: 6.639